This promotional communication is funded and organised by Ipsen, for healthcare professionals only. Prescribing information and adverse event reporting details are available at the end of the page.
A lot has changed within the Progressive Familial Intrahepatic Cholestasis (PFIC) landscape in the last few years. The introduction of Bylvay® (odevixibat) – the first non-surgical biliary diversion treatment for PFIC, has offered the chance to relieve symptoms and modify the disease course with a once-daily oral treatment.1 Prior to this, management relied on nutritional support, symptomatic relief, surgery and liver transplantation.2
By treating cholestasis, Bylvay can reduce serum bile acid levels to relieve pruritus, and could preserve native liver tissue and reduce the need for liver transplant in treatment responders.3,4
Approved in the EU in 2021, Bylvay is supported by long-term phase 3 clinical trial data and a growing body of real-world experience in patients across multiple subtypes of PFIC.1,3
A primer on PFIC
Prescribing Information: Click here for prescribing information.
Adverse event reporting:
| ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions to [email protected] and via the national reporting system as described in section 4.8 of the product prescribing information.. |
References
- Bylvay Summary of Product Characteristics, July 2021.
- Srivastava A. J Clin Exp Hepatol 2014;4(1):25–36.
- Thompson RJ et al. Lancet Gastroenterol Hepatol 2022;7:830–842.
- Clemson C et al. Presented at AASLD The Liver Meeting Nov 4-8, 2022. Washington, DC, USA.
- Baker A et al. Clin Res Hepatol Gastroenterol 2019;43(1):20–36.
- McKiernan P et al. JHEP Rep 2023;6(1):100949.
- Jones-Hughes T et al. Orphanet J Rare Dis 2021;16:255.
- Mighiu C et al. Orphanet J Rare Dis 2022:17(1):32.
BYL-ALL-000874 08/2024
